NCT06004947

A Study in Healthy Volunteers to Evaluate the Drug-Drug Interaction Potential of CCX168 With Concomitant Medications

An Open-Label, Phase 1 Study in Healthy Volunteers to Evaluate the Drug-Drug Interaction Potential of CCX168 With Concomitant Medications

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 32 (actual)
• Sponsor: Amgen · Industry
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

The primary objective of this study will be to evaluate the drug-drug interaction potential of CCX168 with concomitant medications, as either a perpetrator or a victim, following oral administration of CCX168 to healthy participants.

Conditions

• Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis

Interventions

Type	Name	Description
DRUG	CCX168	Administered orally.
DRUG	Midazolam	Administered orally.
DRUG	Celecoxib	Administered orally.
DRUG	Itraconazole	Administered orally.
DRUG	Rifampicin	Administered orally.

Timeline

• Start date: 2016-01-14
• Primary completion: 2016-03-15
• Completion: 2016-06-10
• First posted: 2023-08-22
• Last updated: 2023-08-22

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study